Other News To Note
Friday, December 2, 2011
BioMarin Pharmaceutical Inc., of Novato, Calif., said it completed the buyback of intellectual property (IP) related to Naglazyme (galsulfase) from SA Pathology, a unit of the Central Adelaide Local Health Network in Adelaide, Australia, in exchange for $81 million up front.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.